#Canada #Aurora Cannabis #Edmonton #Fiscal 2025 #medical cannabis

Aurora Cannabis Reports Impressive Fiscal Year 2025 Results

Aurora Cannabis Inc., one of the leading global medical cannabis companies, has unveiled its financial and operational performance for the fiscal year ending March 31, 2025. The company experienced significant growth, highlighting a record net revenue of approximately CAD 244.4 million, signifying a 39% year-over-year increase. This remarkable outcome reflects the company’s strategic initiatives and commitment to growth in the competitive cannabis market.

Key Highlights

During the fiscal year, Aurora achieved an adjusted EBITDA of CAD 49.7 million, a staggering increase of 261% from the previous year. This financial success was complemented by positive free cash flow, amounting to CAD 9.9 million. The company also reported it had maintained a solid balance sheet, holding nearly CAD 185.3 million in cash, with a debt-free cannabis operation.

CEO Miguel Martin expressed his satisfaction in the impressive results, stating, "We are pleased to report an exceptional year to our shareholders, underscoring thoughtful execution of our strategic plan that sets us apart from competitors and strengthens our foundation for sustained and profitable growth."

Fourth Quarter Highlights

In the fourth quarter alone, the company recorded total net revenue of CAD 90.5 million, a significant increase from CAD 67.4 million in the same quarter of the previous year. This gain was driven predominantly by a robust growth trajectory in both the medical cannabis and plant propagation sectors. In particular, medical cannabis net revenue surged by 48%, contributing to CAD 67.8 million, illustrating the company’s strong position in international markets, particularly in regions like Australia, Germany, Poland, and the UK.

In contrast, the consumer cannabis segment noted a year-over-year decline, with net revenues of CAD 8.2 million, a dip attributed to the prioritization of high-margin products within the medical sector. Moreover, the plant propagation revenue reached CAD 13.8 million, up 32% from the prior year, indicating successful organic growth and the expansion of product offerings.

Operational Developments

The financial growth seen in fiscal year 2025 stems not only from an increase in sales but also from improvements in operational efficiencies. Aurora's gross margin before fair value adjustments saw a positive shift from 50% to 62%, showcasing the effectiveness of strategies employed to optimize production processes and cost management. The company's international sales now represent a remarkable 61% of total medical cannabis net revenue, further emphasizing its global footprint.

In view of the upcoming fiscal Q1 2026, Aurora is optimistic about continuing strong revenue growth, especially in Canadian medical markets, although some international segments may witness temporary declines. The company anticipates working comfortably within historical seasonal trends and maintaining positive adjusted EBITDA and free cash flow.

Looking Forward

With aspirations for sustained growth, Aurora’s management remains focused on expanding cannabis distribution capabilities while further innovating product lines. Their commitment to operational excellence, coupled with strategic investments, sets them on a promising path for fiscal year 2026 and beyond.

Aurora will hold a conference call today to discuss these results in further detail, allowing stakeholders to gain insights into the company’s trajectory. For more information on this and future updates, Aurora's stakeholders are encouraged to visit their official website or tune into the upcoming call.

As Aurora Cannabis Inc. advances, it remains committed to improving lives through cannabis, championing quality and innovation in both the medical and consumer markets across Canada, Europe, Australia, and New Zealand.